IP Library › Granted Patent US 12,268,895
Granted Patent B2
US 12,268,895 · App. 18/301,085 · Granted Apr 8, 2025

Joint optimization of radionuclide and external beam radiotherapy

Inventors: Peter Demetri Olcott (Los Gatos, CA); Michael Kirk Owens (North Easton, MA); Debashish Pal (Sunnyvale, CA)
Assignee: RefleXion Medical, Inc.
A61N5/1031A61N5/1039A61N5/1045A61N2005/1024A61N2005/1034A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,895
App. No.
18/301,085
Granted
Apr 8, 2025
Kind
B2
Abstract

Disclosed herein are methods for radiotherapy treatment plan optimization for irradiating one or more target regions using both an internal therapeutic radiation source (ITRS) and an external therapeutic radiation source (ETRS). One variation of a method comprises iterating through ITRS radiation dose values and ETRS radiation dose values to attain a cumulative dose that meets prescribed dose requirements. In some variations, an ITRS is an injectable compound that has a targeting backbone and a radionuclide, and images acquired using an imaging compound that has the same targeting backbone as the injectable compound can be used to calculate the radiation dose deliverable using the injectable ITRS, and also to calculate firing filters for delivering radiation using a biologically-guided radiation therapy (BGRT) system. Image data acquired from a previous treatment session may be used to adapt the dose provided by an ITRS and/or ETRS for a future treatment session.

Claims (41)

1. A method for joint internal and external radiotherapy, the method comprising:

generating a radiotherapy treatment plan that specifies a radiation dose deliverable using an internal therapeutic radiation source (ITRS) and a radiation dose deliverable using an external therapeutic radiation source (ETRS), wherein the ITRS radiation dose and the ETRS radiation doses have been calculated by iterating through intermediate values of the ITRS radiation dose and intermediate values of the ETRS radiation dose to attain a cumulative radiation dose that meets prescribed dose requirements;

delivering radiation in a first treatment session to a patient target region using a radiotherapy system comprising an ETRS movable about a patient target region; and

delivering radiation in a second treatment session using an ITRS to the patient target region.

2. The method of claim 1 , wherein generating the radiotherapy treatment plan comprises calculating the intermediate value of the ITRS radiation dose using functional image data.

3. The method of claim 2 , wherein functional image data comprises PET data, CT data, SPECT data, or combinations thereof.

4. The method of claim 2 , wherein the ITRS comprises an injectable compound and wherein calculating the intermediate value of the ITRS radiation dose uses biodistribution data derived from the functional image data.

5. The method of claim 1 , wherein the prescribed dose requirements include one or more dose constraints.

6. The method of claim 5 , wherein the one or more dose constraints comprises one or more cost functions.

7. The method of claim 6 , wherein the one or more cost functions comprise a cost function on radiation toxicity to a non-target region.

8. The method of claim 6 , wherein the one or more cost functions comprise a cost function on the ITRS radiation dose, ETRS radiation dose, or combinations thereof.

9. The method of claim 1 , wherein the radiotherapy system further comprises a multi-leaf collimator disposed in a radiation beam path of the ETRS and a movable gantry upon which the ETRS is mounted, and wherein delivering radiation in the first treatment session comprises moving the gantry to position the ETRS at radiation emission locations and arranging leaves of the multi-leaf collimator at each of the radiation emission locations in order to deliver the ETRS radiation dose.

10. The method of claim 9 , wherein the radiotherapy system further comprises a plurality of PET detectors, and wherein delivering radiation in the first treatment session comprises arranging leaves of the multi-leaf collimator and emitting radiation from the ETRS in response to PET detector data.

11. The method of claim 1 , wherein delivering radiation in the second treatment session comprises injecting the ITRS into the patient, wherein the ITRS comprises a compound with a targeting backbone and a radionuclide.

12. The method of claim 11 , wherein the targeting backbone is DOTA-TATE and the radionuclide is selected from a group consisting of Ga-68 and Lu-177.

13. The method of claim 11 , wherein the targeting backbone is selected from the group consisting of DOTA-TOC, PSMA-11, PSMA-617, NeoBOMB1, Pentixafor, iobenguane (MIBG), TCMC trastuzumab, MDP, iodine, ibritumomab tiuxetan, SARTATE, thymidine, methionine, misonidazole (MISO), azomycin-arabinoside, erythronitroimidazole, a nitromidazole derivative, folic acid, 5F7 antibody, choline, DCFPyL, DCFBC, PD-1 binding protein, PD-L1 binding protein, PD-L2 binding protein, satoreotide tetraxetan, lexidronam, tositumomab, apamistamab, lilotomab satetraxetan, omburtamab, 3BP-227, fibroblast activation protein (FAP) inhibitor, FAP binding molecule, girentuximab and pentixather, and the radionuclide is selected from the group consisting of NaF-18, F-18, Ga-68, Cu-64, Zr-89, I-124, Sc-44, Tb-152, Y-86, Tc-99m, In-111, Tb-155, I-123, Cu-67, Sr-89, Y-90, I-131, Tb-161, Lu-177, Bi-212, Bi-213, At-211, Ac-225, Th-227, Ra-223, Pb-212, and Tb-149.

14. The method of claim 1 , wherein delivering radiation in the second treatment session comprises implanting the ITRS at the patient target region, wherein the ITRS comprises a radioactive portion and a housing disposed over the radioactive portion.

15. The method of claim 14 , wherein the implantable radiation source comprises a radioactive seed.

16. The method of claim 1 , further comprising:

acquiring functional image data during the first treatment session using the ETRS; and

acquiring functional image data during the second treatment session using the ITRS.

17. The method of claim 16 , further comprises calculating an updated ITRS radiation dose by calculating a radiation dose delivered in the second treatment session using the acquired functional image data from the second treatment session.

18. The method of claim 17 , wherein calculating the updated ITRS radiation dose further comprises calculating a radiation dose delivered in the first treatment session.

19. The method of claim 18 , wherein calculating a radiation dose delivered in the first treatment session uses the functional image data acquired from the first treatment session.

20. The method of claim 17 , further comprising:

calculating an updated ETRS radiation dose,

wherein calculating the updated ITRS radiation dose and the updated ETRS radiation dose comprises

calculating an updated cumulative radiation dose by subtracting radiation doses delivered in the first and second treatment sessions;

iterating through intermediate values of ITRS radiation doses and intermediate values of ETRS radiation doses to attain the updated cumulative radiation dose; and

delivering the updated ITRS radiation dose using the ITRS in a third treatment session.

21. The method of claim 16 , wherein acquiring functional image data comprises acquiring one or more PET image data, CT image data, MRI image data, SPECT image data, or combinations thereof.

22. The method of claim 1 , wherein generating a radiotherapy treatment plan comprises:

acquiring functional image data using a first compound having a first targeting backbone and a first radionuclide; and

iterating through intermediate values of ITRS radiation doses and intermediate values of ETRS radiation doses that have been calculated based on the acquired functional image data,

wherein delivering radiation in the second treatment session uses an ITRS that comprises a second compound having a second targeting backbone and a second radionuclide.

23. The method of claim 22 , wherein the first targeting backbone and the second targeting backbone are the same.

24. The method of claim 22 , wherein the first radionuclide and the second radionuclide are the same.

25. The method of claim 22 , wherein acquiring functional image data comprises acquiring one or more PET image data, CT image data, MRI image data, SPECT image data, or combinations thereof.

26. The method of claim 22 , wherein the functional image data is acquired during a diagnostic imaging session.

27. The method of claim 22 , wherein the functional image data is acquired during a previous treatment session using an ETRS of a radiotherapy system.

28. The method of claim 27 , wherein the functional image data is acquired using an imager of the radiotherapy system.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2023
From: OLCOTT, PETER DEMETRI; OWENS, MICHAEL KIRK; PAL, DEBASHISH
To: REFLEXION MEDICAL, INC.
Reel/Frame 063350/0031 →
Continuity (3)
Continuation 17158848 · Jan 26, 2021
Provisional Application 62966997 · Jan 28, 2020
Related Publication 20230405359A1 · Dec 21, 2023
References Cited (224)
US 4932412A · Goldenberg · 1990 [cited by applicant]
US 5647663A · Holmes · 1997 [cited by applicant]
US 6187037B1 · Satz · 2001 [cited by applicant]
US 6438202B1 · Olivera et al. · 2002 [cited by applicant]
US 6714620B2 · Caflisch et al. · 2004 [cited by applicant]
US 6911200B2 · Yu et al. · 2005 [cited by applicant]
US 8663083B2 · Georgi et al. · 2014 [cited by applicant]
US 8693629B2 · Sgouros et al. · 2014 [cited by applicant]
US 8784846B2 · Schulte et al. · 2014 [cited by applicant]
US 9155909B2 · Ishikawa · 2015 [cited by applicant]
US 9180214B1 · Miao · 2015 [cited by applicant]
US 9198989B2 · Keyak et al. · 2015 [cited by applicant]
US 9320813B2 · Peyman · 2016 [cited by applicant]
US 9340524B2 · Chen et al. · 2016 [cited by applicant]
US 9387342B2 · Prionas et al. · 2016 [cited by applicant]
US 9387344B2 · Sgouros et al. · 2016 [cited by applicant]
US 9597427B2 · Keyak et al. · 2017 [cited by applicant]
US 9757084B2 · Sgouros et al. · 2017 [cited by applicant]
US 9803025B2 · Hettmann et al. · 2017 [cited by applicant]
US 9925283B2 · Weichert et al. · 2018 [cited by applicant]
US 9956428B2 · Kelly · 2018 [cited by applicant]
US 10007961B2 · Grudzinski et al. · 2018 [cited by applicant]
US 10456600B2 · Owens et al. · 2019 [cited by applicant]
US 10521563B2 · Von Busch et al. · 2019 [cited by applicant]
US 10674983B2 · Black · 2020 [cited by applicant]
US 10688320B2 · Voronenko et al. · 2020 [cited by applicant]
US 10918884B2 · O'Connor et al. · 2021 [cited by applicant]
US 11033757B2 · Voronenko et al. · 2021 [cited by applicant]
US 11633626B2 · Voronenko et al. · 2023 [cited by applicant]
US 11648418B2 · Owens et al. · 2023 [cited by applicant]
US 11654300B2 · Olcott et al. · 2023 [cited by applicant]
US 20020137991A1 · Scarantino et al. · 2002 [cited by applicant]
US 20040018968A1 · Sgouros et al. · 2004 [cited by applicant]
US 20040096033A1 · Seppi et al. · 2004 [cited by applicant]
US 20040115203A1 · Dadachova et al. · 2004 [cited by applicant]
US 20050027196A1 · Fitzgerald · 2005 [cited by applicant]
US 20050143965A1 · Failla et al. · 2005 [cited by applicant]
US 20050196340A1 · Holash et al. · 2005 [cited by applicant]
US 20050207531A1 · Dempsey et al. · 2005 [cited by applicant]
US 20050238578A1 · Fritzberg et al. · 2005 [cited by applicant]
US 20060159220A1 · Heuscher · 2006 [cited by applicant]
US 20060228297A1 · Larsen et al. · 2006 [cited by applicant]
US 20060257317A1 · Bigner et al. · 2006 [cited by applicant]
US 20060257369A1 · Kessler et al. · 2006 [cited by applicant]
US 20070093432A1 · Yang · 2007 [cited by applicant]
US 20080193377A1 · Line et al. · 2008 [cited by applicant]
US 20080230705A1 · Rousso et al. · 2008 [cited by applicant]
US 20080247996A1 · Yu et al. · 2008 [cited by applicant]
US 20090054720A1 · Sgouros et al. · 2009 [cited by applicant]
US 20090117044A1 · Hengerer et al. · 2009 [cited by applicant]
US 20100054411A1 · Nord et al. · 2010 [cited by applicant]
US 20100086183A1 · Vik et al. · 2010 [cited by applicant]
US 20100150309A1 · Nord et al. · 2010 [cited by applicant]
US 20100178244A1 · Arnsdorf et al. · 2010 [cited by applicant]
US 20100178245A1 · Arnsdorf et al. · 2010 [cited by applicant]
US 20110086850A1 · Ang et al. · 2011 [cited by applicant]
US 20110122997A1 · Lu et al. · 2011 [cited by applicant]
US 20110135058A1 · Sgouros et al. · 2011 [cited by applicant]
US 20110163238A1 · Teshigawara et al. · 2011 [cited by applicant]
US 20110291015A1 · Mazin · 2011 [cited by applicant]
US 20120292534A1 · Geneser et al. · 2012 [cited by applicant]
US 20120323599A1 · Bal et al. · 2012 [cited by applicant]
US 20130083004A1 · Nord et al. · 2013 [cited by applicant]
US 20130188856A1 · Adler, Jr. et al. · 2013 [cited by applicant]
US 20140005464A1 · Bharat et al. · 2014 [cited by applicant]
US 20140252227A1 · Sasai et al. · 2014 [cited by applicant]
US 20140275704A1 · Zhang et al. · 2014 [cited by applicant]
US 20140343344A1 · Saunders et al. · 2014 [cited by applicant]
US 20150031988A1 · Takeuchi et al. · 2015 [cited by applicant]
US 20150043709A1 · Shapiro et al. · 2015 [cited by applicant]
US 20150050349A1 · Schulte et al. · 2015 [cited by applicant]
US 20150161338A1 · Scherrer et al. · 2015 [cited by applicant]
US 20150196665A1 · Govindan et al. · 2015 [cited by applicant]
US 20150196666A1 · Govindan et al. · 2015 [cited by applicant]
US 20150202319A1 · Govindan et al. · 2015 [cited by applicant]
US 20150251017A1 · De Crevoisier et al. · 2015 [cited by applicant]
US 20160038767A1 · Wiersma et al. · 2016 [cited by applicant]
US 20160074541A1 · Zalutsky et al. · 2016 [cited by applicant]
US 20160213949A1 · Uhlemann et al. · 2016 [cited by applicant]
US 20160256713A1 · Saunders et al. · 2016 [cited by applicant]
US 20160287903A1 · Sgouros et al. · 2016 [cited by applicant]
US 20160361566A1 · Larkin et al. · 2016 [cited by applicant]
US 20170014642A1 · An et al. · 2017 [cited by applicant]
US 20170028220A1 · Schulte et al. · 2017 [cited by applicant]
US 20170087385A1 · Miettinen et al. · 2017 [cited by applicant]
US 20170186153A1 · Enderling et al. · 2017 [cited by applicant]
US 20170327567A1 · Skokos et al. · 2017 [cited by applicant]
US 20180015154A1 · Weichert et al. · 2018 [cited by applicant]
US 20180021461A1 · Weichert et al. · 2018 [cited by applicant]
US 20180126012A1 · Weichert et al. · 2018 [cited by applicant]
US 20180133518A1 · Harper et al. · 2018 [cited by applicant]
US 20180273634A1 · Tran et al. · 2018 [cited by applicant]
US 20180345042A1 · Voronenko et al. · 2018 [cited by applicant]
US 20180369611A1 · Owens et al. · 2018 [cited by applicant]
US 20190114765A1 · Enderling et al. · 2019 [cited by applicant]
US 20190118001A1 · Mazin et al. · 2019 [cited by applicant]
US 20190209731A1 · Keyak et al. · 2019 [cited by applicant]
US 20190218621A1 · Davicioni et al. · 2019 [cited by applicant]
US 20190262451A1 · Kelly · 2019 [cited by applicant]
US 20190381338A1 · Voronenko et al. · 2019 [cited by applicant]
US 20200016283A1 · Cuthbertson · 2020 [cited by applicant]
US 20200023088A1 · Tsai et al. · 2020 [cited by applicant]
US 20230356003A1 · Voronenko et al. · 2023 [cited by applicant]
US 20230390580A1 · Owens et al. · 2023 [cited by applicant]
CN 1824342A · 2006 [cited by applicant]
CN 101496018A · 2009 [cited by applicant]
CN 102068763A · 2011 [cited by applicant]
CN 102641561A · 2012 [cited by applicant]
CN 103180014A · 2013 [cited by applicant]
CN 103845068A · 2014 [cited by applicant]
CN 104284697A · 2015 [cited by applicant]
CN 104866928A · 2015 [cited by applicant]
CN 104994909A · 2015 [cited by applicant]
CN 105658279A · 2016 [cited by applicant]
CN 106563211A · 2017 [cited by applicant]
EP 3539616A1 · 2019 [cited by applicant]
JP 2002522128A · 2002 [cited by applicant]
JP 2012035072A · 2012 [cited by applicant]
JP 2014023741A · 2014 [cited by applicant]
JP 2014527439A · 2014 [cited by applicant]
JP 2016168077A · 2016 [cited by applicant]
JP 2017500165A · 2017 [cited by applicant]
JP 2018007875A · 2018 [cited by applicant]
WO WO0076556A2 · 2000 [cited by applicant]
WO WO0076556A3 · 2000 [cited by applicant]
WO WO03088954A1 · 2003 [cited by applicant]
WO WO2005052721A2 · 2005 [cited by applicant]
WO WO2005052721A3 · 2005 [cited by applicant]
WO WO2005117542A2 · 2005 [cited by applicant]
WO WO2005117542A3 · 2005 [cited by applicant]
WO WO2006012355A2 · 2006 [cited by applicant]
WO WO2006012355A3 · 2006 [cited by applicant]
WO WO2006119285A1 · 2006 [cited by applicant]
WO WO2008057363A2 · 2008 [cited by applicant]
WO WO2008057363A3 · 2008 [cited by applicant]
WO WO2008068717A2 · 2008 [cited by applicant]
WO WO2008068717A3 · 2008 [cited by applicant]
WO WO2008079569A2 · 2008 [cited by applicant]
WO WO2008079569A3 · 2008 [cited by applicant]
WO WO2008130380A2 · 2008 [cited by applicant]
WO WO2008130380A3 · 2008 [cited by applicant]
WO WO2009018383A1 · 2009 [cited by applicant]
WO WO2009031073A2 · 2009 [cited by applicant]
WO WO2009031073A3 · 2009 [cited by applicant]
WO WO2010018477A2 · 2010 [cited by applicant]
WO WO2010018477A3 · 2010 [cited by applicant]
WO WO2010083107A1 · 2010 [cited by applicant]
WO WO2010121153A2 · 2010 [cited by applicant]
WO WO2010121153A3 · 2010 [cited by applicant]
WO WO2013054788A1 · 2013 [cited by applicant]
WO WO2013096776A2 · 2013 [cited by applicant]
WO WO2013096776A3 · 2013 [cited by applicant]
WO WO2015153991A1 · 2015 [cited by applicant]
WO WO2015168431A1 · 2015 [cited by applicant]
WO WO2015179858A1 · 2015 [cited by applicant]
WO WO2016023786A1 · 2016 [cited by applicant]
WO WO2016064750A1 · 2016 [cited by applicant]
WO WO2017133654A1 · 2017 [cited by applicant]
WO WO2017197259A1 · 2017 [cited by applicant]
WO WO2018017526A1 · 2018 [cited by applicant]
WO WO2018022571A1 · 2018 [cited by applicant]
WO WO2018053648A1 · 2018 [cited by applicant]
WO WO2019008040A1 · 2019 [cited by applicant]
WO WO2019094657A1 · 2019 [cited by applicant]
WO WO2019174979A1 · 2019 [cited by applicant]
WO WO2019217928A1 · 2019 [cited by applicant]
Extended European Search Report mailed on May 31, 2024, for EP Application No. 23 211 269.8, filed on Jun. 22, 2018, 5 pages. [cited by applicant]
Geets, X. et al. (Oct. 2007). “Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy… [cited by applicant]
Guohua, H. et al. (Nov. 2002). “Chapter 8: Radionuclide diagnosis and treatment,” in [cited by applicant]
Hongsheng, S. (Aug. 2015). “Chapter 8: Nuclear medicine imaging,” in [cited by applicant]
Non-Final Office Action mailed on Jun. 24, 2024, for U.S. Appl. No. 18/295,448, filed Apr. 4, 2023, 8 pages. [cited by applicant]
Notice of Allowance mailed on Sep. 29, 2024, for U.S. Appl. No. 18/295,448, filed Apr. 4, 2023, 5 pages. [cited by applicant]
Peng, C. et al. (Jun. 2016). “Chapter 15: Clinical radiotherapy technique,” in [cited by applicant]
Shiying, Y. (Jul. 2009). “Chapter 4: Design of radiotherapy plan,” in [cited by applicant]
Xuening, Z. (Dec. 2010). “Chapter 2: Principles and Stereotactic Techniques of LEKSELL Gamma Knife,” in [cited by applicant]
Zhiliao, Z. et al. (Mar. 2002). “Progress in Physics of Tumor Radiotherapy,” Beijing Medical University and China Union Medical University Joint Publishing House, first edition, first printing, pp. 163-164 (with English… [cited by applicant]
Adaptive Radiation Therapy: ISBN:9781439816356. 2011. CRC Press. X Allen Li (Ed.): 426 pages (cover only); URL: https:// www.google.com/books/edition/Adaptive_Radiation_Therapy/9hEPvAlgPfMC (accessed Aug. 31, 2021). [cited by applicant]
Besse, I.M. et al. (2009). “Modeling Combined Radiopharmaceutical Therapy: A Linear Optimization Framework,” Tech. in Cancer Res. and Treatment 8:51-60. [cited by applicant]
Chen, X. et al. (2012). “Smoothing proximal gradient method for general structured sparse regression,” The Annals of Applied Statistics 6:719-752. [cited by applicant]
Corrected Notice of Allowability mailed on Mar. 13, 2023, for U.S. Appl. No. 17/235,812, filed Apr. 20, 2021, 4 pages. [cited by applicant]
Croteau, E. et al. (2016).“PET Metabolic Biomarkers for Cancer,” Biomark Cancer. 8(Suppl 2):61-69. [cited by applicant]
Divgi, C. et al. (2021). “Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy,” Int. J. Radiation Oncol. Biol. Phys. 109:905-9… [cited by applicant]
Extended European Search Report mailed on Oct. 15, 2019, for European Application No. 17 764 132.1, filed on Mar. 9, 2017, 4 pages. [cited by applicant]
Extended European Search Report mailed on Feb. 3, 2021, for EP Application No. 18 810 297.4, filed on May 30, 2018, 4 pages. [cited by applicant]
Extended European Search Report mailed on Jun. 14, 2021, for EP Application No. 18 821 003.3, filed on Jun. 22, 2018, 5 pages. [cited by applicant]
Final Office Action mailed on May 18, 2022, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 31 pages. [cited by applicant]
Fredriksson (2013). “Robust optimization of radiation therapy accounting for geometric uncertainty,” KTH Engin. Sciences, pp. 8-14. [cited by applicant]
Hurwitz, M. (2006). “Combined External Beam Radiotherapy and Brachytherapy for the Management of Prostate Cancer,” Radiation Oncology, pp. 29-32. [cited by applicant]
International Search Report mailed on Jun. 27, 2017, for PCT Patent Application No. PCT/US2017/021647, filed on Mar. 9, 2017, 3 pages. [cited by applicant]
International Search Report mailed on Nov. 16, 2018, for PCT Application No. PCT/US2018/039104, filed on Jun. 22, 2018, 4 pages. [cited by applicant]
International Search Report mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/035188, filed on May 30, 2018, 4 pages. [cited by applicant]
International Search Report mailed on May 6, 2021, for PCT Application No. PCT/US2021/015119, filed on Jan. 26, 2021, 8 pages. [cited by applicant]
James, S.S. et al. (2021). “Current Status of Radiopharmaceutical Therapy,” Int. J. Radiation Oncol. Biol. Phys. 109:891-901. [cited by applicant]
Kim et al. “18F-FDG PET/CT of Advanced Gastric Carcinoma and Association of H ER2 Expression with Standardized Uptake Value.” Asia Oceania J Nucl Med Biol, 2014; 2(1): 12-18. [cited by applicant]
Kong et al. “Effect of Midtreatment PET/CT-Adapted Radiation Therapy with Concurrent Chemotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.” JAMA Oncol. Oct. 2017; 3(10): 1358-1365. Published online … [cited by applicant]
Lassmann, M. et al. (2018). “The Relevance of Dosimetry in Precision Medicine,” J. Nuclear Med. 59:1494-1499. [cited by applicant]
Mayer, R. et al. (1998). “CT-simulator based brachytherapy planner: seed localization and incorporation of biological considerations,” Radiat. Oncol. Investig. 6:35-51. [cited by applicant]
National Cancer Institute (2020). “Radiopharmaceuticals: Radiation therapy enters the molecular age,” 5 total pages. [cited by applicant]
Non-Final Office Action mailed on Dec. 6, 2019, for U.S. Appl. No. 15/993,325, filed May 30, 2018, 8 pages. [cited by applicant]
Non-Final Office Action mailed on Jun. 26, 2020, for U.S. Appl. No. 16/122,735, filed Sep. 5, 2018, 16 pages. [cited by applicant]
Non-Final Office Action mailed on Dec. 22, 2020, for U.S. Appl. No. 16/554,258, filed Aug. 28, 2019, 11 pages. [cited by applicant]
Non-Final Office Action mailed on Sep. 21, 2021, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 34 pages. [cited by applicant]
Non-Final Office Action mailed on Jul. 7, 2022, for U.S. Appl. No. 17/158,848, filed Jan. 26, 2021, 21 pages. [cited by applicant]
Non-Final Office Action mailed on Aug. 30, 2022, for U.S. Appl. No. 17/235,812, filed Apr. 20, 2021, 8 pages. [cited by applicant]
Non-Final Office Action mailed on Nov. 21, 2022, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 27 pages. [cited by applicant]
Notice of Allowance mailed on Dec. 11, 2020, for U.S. Appl. No. 16/122,735, filed Sep. 5, 2018, 10 pages. [cited by applicant]
Notice of Allowance mailed on Apr. 20, 2020, for U.S. Appl. No. 15/993,325, filed May 30, 2018, 7 pages. [cited by applicant]
Notice of Allowance mailed on Apr. 2, 2021, for U.S. Appl. No. 16/554,258, filed Aug. 28, 2019, 7 pages. [cited by applicant]
Notice of Allowance mailed on Jan. 31, 2023, for U.S. Appl. No. 17/158,848, filed Jan. 26, 2021, 9 pages. [cited by applicant]
Notice of Allowance mailed on Feb. 1, 2023, for U.S. Appl. No. 17/235,812, filed Apr. 20, 2021, 7 pages. [cited by applicant]
Notice of Allowance mailed on Mar. 9, 2023, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 8 pages. [cited by applicant]
O'Doherty, J. (2015). “A review of 3D image-based dosimetry, technical considerations and emerging perspectives in [cited by applicant]
St. James, S. (2021). “Current Status of Radiopharmaceutical Therapy,” Int. J. Radiation Oncol. Biol. Phys. 109:891-901. [cited by applicant]
Thorek, D. “Positron lymphography: multimodal, high-resolution, dynamic mapping and resection of lymph nodes after X intradermal injection of 18F-FDG.” J Nucl Med. Sep. 2012;53(9):1438-45. [cited by applicant]
Thorwarth, D. et al. (2010). “Physical radiotherapy treatment planning based on functional PET/CT data,” Radiotherapy Oncology, pp. 317-324. [cited by applicant]
Tuncel, N. “Adaptive radiotherapy from past to future frontiers.” International Journal of Radiology & Radiation Therapy 2021; 8(2):81-84. [cited by applicant]
Xiao, Y. et al. (2021). “Toward Individualized Voxel-Level Dosimetry for Radiopharmaceutical Therapy,” Int. J. Radiation Oncol. Biol. Phys. 109:902-904. [cited by applicant]
Written Opinion of the International Searching Authority mailed on Jun. 27, 2017, for PCT Patent Application No. PCT/US2017/021647, filed on Mar. 9, 2017, 5 pages. [cited by applicant]
Written Opinion of the International Searching Authority mailed on Nov. 16, 2018, for PCT Application No. PCT/US2018/039104, filed on Jun. 22, 2018, 6 pages. [cited by applicant]
Written Opinion of the International Searching Authority mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/035188, filed on May 30, 2018, 28 pages. [cited by applicant]
Written Opinion of the International Searching Authority mailed on May 6, 2021, for PCT Application No. PCT/US2021/015119, filed on Jan. 26, 2021, 9 pages. [cited by applicant]
Yan, D. et al. (1997). “Adaptive radiation therapy,” [cited by applicant]
Zhang, H. et al. (2002). Progress in the Physics of Tumor Radiation Therapy, Beijing Medical University, China Union Medical University Joint Press, p. 164 (with English translation). [cited by applicant]
Zhao, H. et al. (2015). Practical Imaging Diagnosis, University Press, Aug. 2015, p. 167 (with English translation). [cited by applicant]